Modus Therapeutics Holding AB

So there, then I say welcome to today's report comment from Modus Therapeutics, where I usually have with me VD John Öd. And you who are watching this live can, as usual, anytime in the comments, ask questions to John during the interview, so I try to get them in where it fits or towards the end of our discussion here. John, bra rapport. Ni får fortsätta framgångar här under Q3 och ni skriver i rapporten att tredje kvartalet plagades av stark leverans av kliniska planer, framgångsrik finansiering och växande förutsättningar för partnerskap. Jag tänker att vi kan diskutera utifrån de tre punkterna egentligen. Om vi börjar med... what you have delivered in studies, so to speak, the clinical plans, what do you have to say there? What are the major highlights in the context?

Well, you can really say that we have... The speed we have, it started already in December last year, actually, with the recruitment of part one and part one of the study. And it was delivered in a single plan, that is, we had the results in June, and then send it in, and then be able to draw the conclusions we needed to put the doses in part two and then send it in in August as planned to be able to keep our clinical plans. So actually, we can say that we have gone on a rampage. We have kept our clinical plan and it is actually always a challenge when you recruit patients into a clinical study, chronically ill patients who have a lot of complications, where it creates, so to speak, unpredictability for us who are trying to plan a clinical study. And then it is, so to speak, a good signal that we still manage to keep our plans just as we have thought. So to keep the deliveries in clinical research is really something to maintain as an advantage, actually.

We might also remind the viewers what this is for the study and the timeline for it, so to speak.